Sysmex（0YX）株式概要シスメックス株式会社は日本で診断機器、試薬、関連ソフトウェアの開発、製造、販売を行っている。 詳細0YX ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長1/6過去の実績2/6財務の健全性5/6配当金4/6報酬収益は年間13.52%増加すると予測されています リスク分析German市場と比較した過去 3 か月間の株価の変動2.83%の配当はフリーキャッシュフローで十分にカバーされていない 利益率(7.1%)は昨年より低い(10.6%) すべてのリスクチェックを見る0YX Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€7.104.2% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture0659b2016201920222025202620282031Revenue JP¥659.2bEarnings JP¥46.7bAdvancedSet Fair ValueView all narrativesSysmex Corporation 競合他社Ottobock SE KGaASymbol: XTRA:OBCKMarket cap: €3.3bCarl Zeiss MeditecSymbol: XTRA:AFXMarket cap: €2.2bDrägerwerk KGaASymbol: XTRA:DRW3Market cap: €1.4bEckert & ZieglerSymbol: XTRA:EUZMarket cap: €954.9m価格と性能株価の高値、安値、推移の概要Sysmex過去の株価現在の株価JP¥7.1052週高値JP¥15.0052週安値JP¥6.51ベータ0.651ヶ月の変化6.90%3ヶ月変化0%1年変化-50.00%3年間の変化-65.65%5年間の変化-77.10%IPOからの変化-36.43%最新ニュースNew Risk • Jun 11New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risks Dividend is not well covered by cash flows (108% cash payout ratio). Profit margins are more than 30% lower than last year (7.1% net profit margin).お知らせ • Jun 06Sysmex Corporation to Report Q1, 2027 Results on Aug 07, 2026Sysmex Corporation announced that they will report Q1, 2027 results on Aug 07, 2026Valuation Update With 7 Day Price Move • Jun 01Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €8.02, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 17x in the Medical Equipment industry in Germany. Total loss to shareholders of 61% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €7.89 per share.Reported Earnings • May 20Full year 2026 earnings released: EPS: JP¥56.89 (vs JP¥86.07 in FY 2025)Full year 2026 results: EPS: JP¥56.89 (down from JP¥86.07 in FY 2025). Revenue: JP¥500.0b (down 1.7% from FY 2025). Net income: JP¥35.5b (down 34% from FY 2025). Profit margin: 7.1% (down from 11% in FY 2025). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 5.5% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 30% per year, which means it is performing significantly worse than earnings.お知らせ • May 15Sysmex Corporation, Annual General Meeting, Jun 26, 2026Sysmex Corporation, Annual General Meeting, Jun 26, 2026.お知らせ • Apr 02Sysmex Corporation to Report Fiscal Year 2026 Results on May 14, 2026Sysmex Corporation announced that they will report fiscal year 2026 results at 3:30 PM, Tokyo Standard Time on May 14, 2026最新情報をもっと見るRecent updatesNew Risk • Jun 11New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risks Dividend is not well covered by cash flows (108% cash payout ratio). Profit margins are more than 30% lower than last year (7.1% net profit margin).お知らせ • Jun 06Sysmex Corporation to Report Q1, 2027 Results on Aug 07, 2026Sysmex Corporation announced that they will report Q1, 2027 results on Aug 07, 2026Valuation Update With 7 Day Price Move • Jun 01Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €8.02, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 17x in the Medical Equipment industry in Germany. Total loss to shareholders of 61% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €7.89 per share.Reported Earnings • May 20Full year 2026 earnings released: EPS: JP¥56.89 (vs JP¥86.07 in FY 2025)Full year 2026 results: EPS: JP¥56.89 (down from JP¥86.07 in FY 2025). Revenue: JP¥500.0b (down 1.7% from FY 2025). Net income: JP¥35.5b (down 34% from FY 2025). Profit margin: 7.1% (down from 11% in FY 2025). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 5.5% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 30% per year, which means it is performing significantly worse than earnings.お知らせ • May 15Sysmex Corporation, Annual General Meeting, Jun 26, 2026Sysmex Corporation, Annual General Meeting, Jun 26, 2026.お知らせ • Apr 02Sysmex Corporation to Report Fiscal Year 2026 Results on May 14, 2026Sysmex Corporation announced that they will report fiscal year 2026 results at 3:30 PM, Tokyo Standard Time on May 14, 2026お知らせ • Mar 26Denka Company Limited (TSE:4061) completed the acquisition of 77.65% stake in KAINOS Laboratories, Inc. (TSE:4556) from a group of shareholders.Denka Company Limited (TSE:4061) proposed to acquire 77.65% stake in KAINOS Laboratories, Inc. (TSE:4556) from a group of shareholders for ¥7.9 billion on February 6, 2026. A cash consideration of ¥7.89 billion valued at ¥2285 per share will be paid by Denka Company Limited. As part of consideration, ¥7.89 billion is paid towards common equity of KAINOS Laboratories, Inc. Denka Company Limited intends to launch a Squeeze-Out Procedures, if it acquires the minimum tender shares (1,990,000 shares) and fails to acquire all of the KAINOS Laboratories, Inc's Shares (excluding the Shares Agreed Not to Be Tendered and treasury shares). The transaction is subject to minimum tender. The expected completion of the transaction is March 25, 2026. Sumitomo Mitsui Banking Corporation acted as financial advisor for Denka Company Limited. AGS Consulting Co., Ltd. acted as financial advisor for KAINOS Laboratories, Inc. Nagashima Ohno & Tsunematsu acted as legal advisor for KAINOS Laboratories, Inc. TMI Associates acted as legal advisor for KAINOS Laboratories, Inc. Mizuho Securities Co., Ltd. acted as financial advisor for KAINOS Laboratories, Inc. Denka Company Limited (TSE:4061) completed the acquisition of 77.65% stake in KAINOS Laboratories, Inc. (TSE:4556) from a group of shareholders on March 25, 2026. Upon closing of the offer period, 3,223,919 shares were tendered. Since it is more than the minimum number of shares to be purchased (1,990,000 shares), Denka Company Limited will purchase all of the Tendered Share Certificates and intends to implement a series of procedures for the purpose of making the Tender Offeror the sole shareholder of KAINOS Laboratories, Inc. As of today, the KAINOS Laboratories, Inc's Shares are listed on the Standard Market of the Tokyo Stock Exchange. If the procedures are implemented, the KAINOS Laboratories, Inc's Shares will be delisted pursuant to the prescribed procedures, in accordance with the criteria for delisting of Tokyo Stock Exchange. KAINOS Laboratories, Inc's Shares, after being delisted, will no longer be traded on the Standard Market of the Tokyo Stock Exchange.お知らせ • Mar 05Sysmex Corporation (TSE:6869) announces an Equity Buyback for 30,000,000 shares, representing 4.81% for ¥30,000 million.Sysmex Corporation (TSE:6869) announces a share repurchase program. Under the program, the company will repurchase up to 30,000,000 shares, representing 4.81% of its issued share capital, for ¥30,000 million. The program will be valid till September 18, 2026. The purpose of the program is to improve capital efficiency and enhance shareholder returns as well as active business investment for our future growth. The purchased shares will be cancelled. As of December 31, 2025, the company had 623,180,031 outstanding shares (excluding treasury stock) and 6,300,045 treasury shares.お知らせ • Feb 13Sysmex Corporation Revises Consolidated Earnings Guidance for the Year Ending March 31, 2026Sysmex Corporation revised consolidated earnings guidance for the year ending March 31, 2026. For the year period, the company expects net sales of JPY 500,000 million compared to previous guidance of JPY 510,000 million, operating profit of JPY 62,000 million compared to previous guidance of JPY 76,000 million and profit attributable to owners of the parent of JPY 41,000 million or JPY 65.77 per basic share compared to previous guidance of JPY 45,000 million or JPY 72.19 per basic share.お知らせ • Feb 12Sysmex Corporation Announces Executive and Board Changes, Effective April 1, 2026Sysmex Corporation announced that it has resolved, at a meeting of the Board of Directors held on February 12, 2026, to change the representative directors as stated below. Reasons for Change. To further strengthen management structure in order to enhance corporate value. Iwane Matsui has been newly appointed as the President (Representative Director), while previously serving as Member of the Managing Board and Senior Executive Officer, Senior Managing Director. Kaoru Asano appointed as the Member of the Managing Board, from currently holding the title of President (Representative Director). Effective Date of Transfer: April 1, 2026. Kaoru Asano is scheduled to resign from the Member of the Managing Board at the Ordinary General Meeting of Shareholders to be held in June 2026 and subsequently serve as Senior Executive Advisor. There are no changes to Hisashi Ietsugu's current position as Chairperson and Group CEO. Iwane Matsui was born on January 1, 1961, and graduated from Kobe University with a Bachelor of Faculty of Law in March 1985. He joined TOA Medical Electronics Co. Ltd. (presently Sysmex Corporation) in April 1985. His career progressed through various roles, including serving as President of Sysmex Europe GmbH (presently Sysmex Europe SE) from 2001 to 2005, and later as Executive Vice Chairman & CEO of Sysmex Europe GmbH from 2005 to 2007. He held the position of Executive Vice President of the Customer Support Division from 2007 to 2009, followed by Executive Vice President of the IVD Business Strategy Division from 2009 to 2011. From 2011 to 2013, he served as Executive Officer and Executive Vice President of Corporate Business Planning, and from 2013 to 2015, he was an Executive Officer and Executive Vice President of International Business Management. He then became a Senior Executive Officer from 2017 to 2019, and a Managing Director in 2019. He was appointed as a Member of the Managing Board and Senior Executive Officer in June 2019 and has held the same position since April 2023, also serving as a Senior Managing Director.お知らせ • Feb 09Denka Company Limited (TSE:4061) proposed to acquire 77.65% stake in KAINOS Laboratories, Inc. (TSE:4556) from a group of shareholders for ¥7.9 billion.Denka Company Limited (TSE:4061) proposed to acquire 77.65% stake in KAINOS Laboratories, Inc. (TSE:4556) from a group of shareholders for ¥7.9 billion on February 6, 2026. A cash consideration of ¥7.89 billion valued at ¥2285 per share will be paid by Denka Company Limited. As part of consideration, ¥7.89 billion is paid towards common equity of KAINOS Laboratories, Inc. The transaction is subject to minimum tender. The expected completion of the transaction is March 25, 2026. Sumitomo Mitsui Banking Corporation acted as financial advisor for Denka Company Limited. AGS Consulting Co., Ltd. acted as financial advisor for KAINOS Laboratories, Inc. Nagashima Ohno & Tsunematsu acted as legal advisor for KAINOS Laboratories, Inc. TMI Associates acted as legal advisor for KAINOS Laboratories, Inc. Mizuho Securities Co., Ltd. acted as financial advisor for KAINOS Laboratories, Inc.お知らせ • Dec 05Sysmex Corporation to Report Q3, 2026 Results on Feb 12, 2026Sysmex Corporation announced that they will report Q3, 2026 results on Feb 12, 2026お知らせ • Nov 06+ 2 more updatesSysmex Corporation Revises Consolidated Earnings Guidance for the Year Ending March 31, 2026Sysmex Corporation revised consolidated earnings guidance for the year ending March 31, 2026. For the year ending March 31, 2026, the company expects net sales of JPY 510,000 million compared to previous guidance of JPY 535,000 million, operating profit of JPY 76,000 million compared to previous guidance of JPY 91,500 million and profit attributable to owners of the parent of JPY 45,000 million or JPY 72.19 per basic share compared to previous guidance of JPY 57,000 million or JPY 91.40 per basic share. Reasons for Forecast Revision: Although the company worked to control selling, general and administrative (SG&A) expenses, the company was unable to offset the decline in profit resulting from lower-than-expected net sales. As a result, operating profit, profit before tax, and profit attributable to owners of the parent all fell below the previous forecast. As for its forecast for the full fiscal year ending March 31, 2026, it will continue working to improve profitability and control SG&A expenses. However, given the expectation that sales in the China and Japan regions will remain below initial projections, the company is revising its forecast to reflect anticipated declines in net sales, operating profit, profit before tax, and profit attributable to owners of the parent.お知らせ • Sep 04Sysmex Corporation to Report Q2, 2026 Results on Nov 05, 2025Sysmex Corporation announced that they will report Q2, 2026 results on Nov 05, 2025お知らせ • Jun 25+ 1 more updateSysmex America, Inc. Receives FDA Clearance for Automated Blood Coagulation Analyzer CN-6000™?Sysmex America Inc. has received FDA clearance for the CN-6000 Automated Blood Coagulation Analyzer. This clearance includes the reagent products used in five commonly performed hemostasis tests: Prothrombin Time (PT) and PT INR with Dade®? Innovin®? Activated Partial Thromboplastin Time (APTT) with Dade®? Actin®? FSL; Fibrinogen (Fbg) with Dade®? Thrombin Reagent; Antithrombin (AT) with INNOVANCE®? Antithrombin; D-dimer with INNOVANCE D-Dimmer. Laboratories with high workloads may opt for the optional sampler that provides an expandable sample loading capacity. Sysmex will continue efforts to obtain market authorization for the Automated Blood Coagulation Analyzer CN-3000 and additional reagent applications.お知らせ • Jun 07Sysmex Corporation to Report Q1, 2026 Results on Aug 06, 2025Sysmex Corporation announced that they will report Q1, 2026 results on Aug 06, 2025お知らせ • May 15Sysmex Corporation, Annual General Meeting, Jun 27, 2025Sysmex Corporation, Annual General Meeting, Jun 27, 2025.お知らせ • Feb 28Sysmex Corporation to Report Fiscal Year 2025 Results on May 14, 2025Sysmex Corporation announced that they will report fiscal year 2025 results on May 14, 2025Reported Earnings • Nov 09Second quarter 2025 earnings released: EPS: JP¥24.01 (vs JP¥21.60 in 2Q 2024)Second quarter 2025 results: EPS: JP¥24.01 (up from JP¥21.60 in 2Q 2024). Revenue: JP¥130.5b (up 11% from 2Q 2024). Net income: JP¥15.0b (up 10% from 2Q 2024). Profit margin: 12% (in line with 2Q 2024). Revenue is forecast to grow 8.0% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.お知らせ • Oct 03D-Group S.p.A. acquired an unknown minority stake in Dasit S.p.A. from Sysmex Corporation (TSE:6869).D-Group S.p.A. acquired an unknown minority stake in Dasit S.p.A. from Sysmex Corporation (TSE:6869) on October 2, 2024. Francesco Stella of Hogan Lovells acted as legal advisor for Sysmex Corporation. D-Group S.p.A. completed the acquisition of an unknown minority stake in Dasit S.p.A. from Sysmex Corporation (TSE:6869) on October 2, 2024.New Risk • Oct 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Upcoming Dividend • Sep 20Upcoming dividend of JP¥15.00 per shareEligible shareholders must have bought the stock before 27 September 2024. Payment date: 04 December 2024. Payout ratio is a comfortable 34% and the cash payout ratio is 87%. Trailing yield: 1.1%. Lower than top quartile of German dividend payers (4.8%). Lower than average of industry peers (1.9%).Reported Earnings • Aug 08First quarter 2025 earnings released: EPS: JP¥17.69 (vs JP¥13.73 in 1Q 2024)First quarter 2025 results: EPS: JP¥17.69 (up from JP¥13.73 in 1Q 2024). Revenue: JP¥111.9b (up 17% from 1Q 2024). Net income: JP¥11.0b (up 28% from 1Q 2024). Profit margin: 9.9% (in line with 1Q 2024). Revenue is forecast to grow 7.8% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.Buy Or Sell Opportunity • Aug 04Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 14% to €14.50. The fair value is estimated to be €18.15, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 7.8%. For the next 3 years, revenue is forecast to grow by 8.0% per annum. Earnings are also forecast to grow by 13% per annum over the same time period.Declared Dividend • Jul 11Final dividend of JP¥15.00 announcedShareholders will receive a dividend of JP¥15.00. Ex-date: 27th September 2024 Payment date: 4th December 2024 Dividend yield will be 108%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by earnings (35% earnings payout ratio) but not covered by cash flows (136% cash payout ratio). The dividend has increased by an average of 16% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 44% over the next 3 years, which should provide support to the dividend and adequate earnings cover.お知らせ • Jun 27+ 2 more updatesSysmex Corporation to Report Q3, 2025 Results on Feb 12, 2025Sysmex Corporation announced that they will report Q3, 2025 results on Feb 12, 2025Reported Earnings • Jun 26Full year 2024 earnings released: EPS: JP¥238 (vs JP¥72.94 in FY 2023)Full year 2024 results: EPS: JP¥238 (up from JP¥72.94 in FY 2023). Revenue: JP¥461.5b (up 12% from FY 2023). Net income: JP¥49.6b (up 8.4% from FY 2023). Profit margin: 11% (in line with FY 2023). Revenue is forecast to grow 8.0% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.お知らせ • May 12Sysmex Corporation, Annual General Meeting, Jun 21, 2024Sysmex Corporation, Annual General Meeting, Jun 21, 2024.Reported Earnings • May 10Full year 2024 earnings released: EPS: JP¥238 (vs JP¥72.94 in FY 2023)Full year 2024 results: EPS: JP¥238 (up from JP¥72.94 in FY 2023). Revenue: JP¥461.5b (up 12% from FY 2023). Net income: JP¥49.6b (up 8.4% from FY 2023). Profit margin: 11% (in line with FY 2023). Revenue is forecast to grow 7.3% p.a. on average during the next 3 years, compared to a 7.0% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.Buy Or Sell Opportunity • Apr 26Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 9.4% to €14.50. The fair value is estimated to be €18.41, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 9.5%. For the next 3 years, revenue is forecast to grow by 7.9% per annum. Earnings are also forecast to grow by 13% per annum over the same time period.Buy Or Sell Opportunity • Apr 11Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 15% to €14.80. The fair value is estimated to be €18.64, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 9.5%. For the next 3 years, revenue is forecast to grow by 7.9% per annum. Earnings are also forecast to grow by 13% per annum over the same time period.New Risk • Mar 27New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. Cash payout ratio: 293% Dividend yield: 3.1% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company.Upcoming Dividend • Mar 21Upcoming dividend of JP¥42.00 per shareEligible shareholders must have bought the stock before 28 March 2024. Payment date: 26 June 2024. Payout ratio is a comfortable 38% and the cash payout ratio is 98%. Trailing yield: 1.0%. Lower than top quartile of German dividend payers (5.0%). Lower than average of industry peers (1.6%).お知らせ • Mar 08Sysmex Corporation to Report Fiscal Year 2024 Results on May 09, 2024Sysmex Corporation announced that they will report fiscal year 2024 results on May 09, 2024Reported Earnings • Feb 11Third quarter 2024 earnings released: EPS: JP¥58.90 (vs JP¥53.51 in 3Q 2023)Third quarter 2024 results: EPS: JP¥58.90 (up from JP¥53.51 in 3Q 2023). Revenue: JP¥113.8b (up 8.7% from 3Q 2023). Net income: JP¥12.3b (up 9.7% from 3Q 2023). Profit margin: 11% (in line with 3Q 2023). Revenue is forecast to grow 7.7% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.お知らせ • Feb 09Sysmex Corporation Reaffirm Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2024Sysmex Corporation announced year-end dividend for the fiscal year ending March 31, 2024, with a record date of March 31, 2024, will be paid on the shares before the stock split, because the effective date of the share split is April 1, 2024. The year-end dividend forecast for the fiscal year ending March 31, 2024 remains unchanged from that the announcement on May 11, 2023, which forecasts the year-end dividend of ¥42 per share.お知らせ • Nov 30Sysmex Corporation to Report Q3, 2024 Results on Feb 09, 2024Sysmex Corporation announced that they will report Q3, 2024 results on Feb 09, 2024Reported Earnings • Nov 09Second quarter 2024 earnings released: EPS: JP¥64.81 (vs JP¥76.28 in 2Q 2023)Second quarter 2024 results: EPS: JP¥64.81 (down from JP¥76.28 in 2Q 2023). Revenue: JP¥117.3b (up 8.7% from 2Q 2023). Net income: JP¥13.6b (down 15% from 2Q 2023). Profit margin: 12% (down from 15% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 7.6% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.Upcoming Dividend • Sep 22Upcoming dividend of JP¥42.00 per share at 1.1% yieldEligible shareholders must have bought the stock before 28 September 2023. Payment date: 05 December 2023. Payout ratio is a comfortable 36% and this is well supported by cash flows. Trailing yield: 1.1%. Lower than top quartile of German dividend payers (4.8%). Lower than average of industry peers (2.0%).お知らせ • Sep 08Sysmex Corporation to Report Q2, 2024 Results on Nov 08, 2023Sysmex Corporation announced that they will report Q2, 2024 results on Nov 08, 2023Reported Earnings • Aug 09First quarter 2024 earnings released: EPS: JP¥41.20 (vs JP¥38.38 in 1Q 2023)First quarter 2024 results: EPS: JP¥41.20 (up from JP¥38.38 in 1Q 2023). Revenue: JP¥95.4b (up 11% from 1Q 2023). Net income: JP¥8.62b (up 7.4% from 1Q 2023). Profit margin: 9.0% (down from 9.3% in 1Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 7.3% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.お知らせ • Jun 03Sysmex Corporation to Report Q1, 2024 Results on Aug 08, 2023Sysmex Corporation announced that they will report Q1, 2024 results at 3:00 PM, Tokyo Standard Time on Aug 08, 2023Reported Earnings • May 15Full year 2023 earnings released: EPS: JP¥219 (vs JP¥211 in FY 2022)Full year 2023 results: EPS: JP¥219 (up from JP¥211 in FY 2022). Revenue: JP¥410.5b (up 13% from FY 2022). Net income: JP¥45.8b (up 3.8% from FY 2022). Profit margin: 11% (in line with FY 2022). Revenue is forecast to grow 7.8% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.お知らせ • May 13Sysmex Corporation, Annual General Meeting, Jun 23, 2023Sysmex Corporation, Annual General Meeting, Jun 23, 2023.Upcoming Dividend • Mar 23Upcoming dividend of JP¥40.00 per share at 0.9% yieldEligible shareholders must have bought the stock before 30 March 2023. Payment date: 27 June 2023. Payout ratio is a comfortable 36% but the company is paying out more than the cash it is generating. Trailing yield: 0.9%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (1.7%).Reported Earnings • Feb 13Third quarter 2023 earnings released: EPS: JP¥53.51 (vs JP¥50.96 in 3Q 2022)Third quarter 2023 results: EPS: JP¥53.51 (up from JP¥50.96 in 3Q 2022). Revenue: JP¥104.7b (up 16% from 3Q 2022). Net income: JP¥11.2b (up 5.1% from 3Q 2022). Profit margin: 11% (down from 12% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 7.4% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.お知らせ • Feb 07Sysmex Corporation Announces Management ChangesSysmex Corporation announced that it has resolved, at a meeting of the Board of Directors held on February 7, 2023, to change the representative directors. Kaoru Asano appointed as President (Representative Director) from Member of the Managing Board and Senior Executive Officer, Senior Managing Director, CTO. Appointment Date (Scheduled): April 1, 2023. Date of birth: October 19, 1958. Education: Graduate School of Engineering Osaka University, Division of Electronic Engineering. 2021- Member of the Managing Board and Senior Executive Officer, Senior Managing Director, CTO; 2018-2021 Member of the Managing Board and Senior Executive Officer, Senior Managing Director, COO LS Business Unit and CTO; 2017-2018 Member of the Managing Board and Senior Executive Officer, Senior Managing Director; 2015-2017 Member of the Managing Board and Senior Executive Officer, Managing Director; 2014-2015 Appointed Member of the Managing Board and Senior Executive Officer. 2013-2014 -Appointed Senior Executive Officer, Executive Vice President of Central Research Laboratories; 2011-2013 Appointed Executive Officer, Executive Vice President of R&D Strategic Planning; 2009-2011 Appointed Executive Officer, Executive Vice President of Central Research Laboratories; Aug. 1987 Joined TOA Medical Electronics (presently Sysmex Corporation); Apr. 1983 Joined Kawasaki Heavy Industries Ltd.; March 1983 Graduated from Osaka University. Hisashi Ietsugu: Current: Chairman and CEO (Representative Director); New: Chairman and Group CEO, (Representative Director).お知らせ • Jan 11Sysmex America, Inc. Appoints Chris Cappella as Chief Financial OfficerSysmex America Inc. announced that Chris Cappella has joined the Company as Chief Financial Officer. He will lead Sysmex America's regional finance organization and financial activities including accounting and controllership, financial planning and analysis, tax, internal audit and treasury. to joining Sysmex, Chris held a variety of finance leadership roles at Roche, most recently as the vice president of finance for Core Lab. At Roche, he was instrumental in driving growth through the cross-functional integration of agile strategies. Before his time at Roche, Chris was a finance manager at Brightpoint Inc. He started his career at Ernst & Young and is a Certified Public Accountant.お知らせ • Dec 01Sysmex Corporation to Report Q3, 2023 Results on Feb 09, 2023Sysmex Corporation announced that they will report Q3, 2023 results on Feb 09, 2023Reported Earnings • Nov 17Second quarter 2023 earnings released: EPS: JP¥76.28 (vs JP¥58.61 in 2Q 2022)Second quarter 2023 results: EPS: JP¥76.28 (up from JP¥58.61 in 2Q 2022). Revenue: JP¥108.0b (up 21% from 2Q 2022). Net income: JP¥16.0b (up 30% from 2Q 2022). Profit margin: 15% (up from 14% in 2Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 7.7% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.Board Change • Nov 17Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 5 independent directors. 7 non-independent directors. Independent Outside Member of the Managing Board Hidekazu Fukumoto was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.Reported Earnings • Nov 11Second quarter 2023 earnings released: EPS: JP¥76.28 (vs JP¥58.61 in 2Q 2022)Second quarter 2023 results: EPS: JP¥76.28 (up from JP¥58.61 in 2Q 2022). Revenue: JP¥108.0b (up 21% from 2Q 2022). Net income: JP¥16.0b (up 30% from 2Q 2022). Profit margin: 15% (up from 14% in 2Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 7.7% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.Upcoming Dividend • Sep 22Upcoming dividend of JP¥40.00 per shareEligible shareholders must have bought the stock before 29 September 2022. Payment date: 06 December 2022. Payout ratio is a comfortable 38% but the company is paying out more than the cash it is generating. Trailing yield: 1.0%. Lower than top quartile of German dividend payers (5.1%). Lower than average of industry peers (1.8%).お知らせ • Sep 14Sysmex Corporation to Report Q2, 2023 Results on Nov 09, 2022Sysmex Corporation announced that they will report Q2, 2023 results on Nov 09, 2022Reported Earnings • Aug 05First quarter 2023 earnings released: EPS: JP¥38.38 (vs JP¥47.81 in 1Q 2022)First quarter 2023 results: EPS: JP¥38.38 (down from JP¥47.81 in 1Q 2022). Revenue: JP¥86.0b (up 8.4% from 1Q 2022). Net income: JP¥8.03b (down 20% from 1Q 2022). Profit margin: 9.3% (down from 13% in 1Q 2022). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 14%, compared to a 7.2% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 6% per year whereas the company’s share price has increased by 5% per year.お知らせ • Jun 18Sysmex Corporation to Report Q1, 2023 Results on Aug 04, 2022Sysmex Corporation announced that they will report Q1, 2023 results on Aug 04, 2022Buying Opportunity • Jun 17Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 14%. The fair value is estimated to be €69.73, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.6% over the last 3 years. Earnings per share has grown by 2.7%. For the next 3 years, revenue is forecast to grow by 8.1% per annum. Earnings is also forecast to grow by 12% per annum over the same time period.Reported Earnings • May 15Full year 2022 earnings released: EPS: JP¥211 (vs JP¥159 in FY 2021)Full year 2022 results: EPS: JP¥211 (up from JP¥159 in FY 2021). Revenue: JP¥363.8b (up 19% from FY 2021). Net income: JP¥44.1b (up 33% from FY 2021). Profit margin: 12% (up from 11% in FY 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 8.7%, compared to a 7.1% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 1% per year.お知らせ • May 14Sysmex Corporation, Annual General Meeting, Jun 24, 2022Sysmex Corporation, Annual General Meeting, Jun 24, 2022.Board Change • Apr 27Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, 4 were independent directors. The company's board is composed of: 5 independent directors. 7 non-independent directors. Independent Outside Member of the Managing Board Hidekazu Fukumoto was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.お知らせ • Apr 04Sysmex Corporation to Report Fiscal Year 2022 Results on May 12, 2022Sysmex Corporation announced that they will report fiscal year 2022 results at 3:00 PM, Tokyo Standard Time on May 12, 2022Upcoming Dividend • Mar 23Upcoming dividend of JP¥37.00 per shareEligible shareholders must have bought the stock before 30 March 2022. Payment date: 28 June 2022. Payout ratio is a comfortable 36% and this is well supported by cash flows. Trailing yield: 0.9%. Lower than top quartile of German dividend payers (3.6%). Lower than average of industry peers (1.1%).Buying Opportunity • Mar 12Now 23% undervalued after recent price dropOver the last 90 days, the stock is down 43%. The fair value is estimated to be JP¥81.89, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.2% per annum over the last 3 years. Earnings per share has been flat over the last 3 years.Valuation Update With 7 Day Price Move • Mar 02Investor sentiment improved over the past weekAfter last week's 17% share price gain to €74.00, the stock trades at a forward P/E ratio of 38x. Average forward P/E is 34x in the Medical Equipment industry in Germany. Total returns to shareholders of 43% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €86.16 per share.Reported Earnings • Feb 11Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: EPS: JP¥50.96 (up from JP¥50.90 in 3Q 2021). Revenue: JP¥90.1b (up 13% from 3Q 2021). Net income: JP¥10.7b (flat on 3Q 2021). Profit margin: 12% (down from 13% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 8.9%, compared to a 12% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has increased by 14% per year, which means it is well ahead of earnings.Valuation Update With 7 Day Price Move • Jan 08Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to €95.50, the stock trades at a forward P/E ratio of 54x. Average forward P/E is 36x in the Medical Equipment industry in Germany. Total returns to shareholders of 127% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €75.84 per share.Reported Earnings • Nov 11Second quarter 2022 earnings released: EPS JP¥58.61 (vs JP¥39.09 in 2Q 2021)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2022 results: Revenue: JP¥89.4b (up 25% from 2Q 2021). Net income: JP¥12.3b (up 50% from 2Q 2021). Profit margin: 14% (up from 11% in 2Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 28% per year, which means it is well ahead of earnings.Upcoming Dividend • Sep 22Upcoming dividend of JP¥37.00 per shareEligible shareholders must have bought the stock before 29 September 2021. Payment date: 01 December 2021. Trailing yield: 0.5%. Lower than top quartile of German dividend payers (3.2%). Lower than average of industry peers (0.8%).Valuation Update With 7 Day Price Move • Sep 14Investor sentiment improved over the past weekAfter last week's 18% share price gain to €109, the stock trades at a forward P/E ratio of 58x. Average forward P/E is 47x in the Medical Equipment industry in Germany. Total returns to shareholders of 51% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €94.76 per share.お知らせ • Jun 03Sysmex America Adds FDA-Cleared XN-10 Blood Bank Mode to Hematology Solutions PortfolioSysmex America Inc., has added the FDA-cleared XN-10 Automated Hematology Analyzer with Blood Bank mode to its portfolio of hematology solutions. This latest analyzer supports red blood cell and platelet component testing and provides an automated complete blood count with differential for whole blood samples. The company is the first and only original equipment manufacturer of Automated Hematology devices to receive FDA-cleared intended use claims for the Blood Center/Blood Bank market. The XN Blood Bank mode is intended for use in blood processing centers for QC release testing of post-processed components. Blood component quality is key in transfusion medicine and blood product manufacturing. Sysmex America's XN Blood Bank mode is a holistic solution that offers accurate cell counts on products that are key to blood centers and blood banks. With no sample preparation or pre-dilution required, the XN Blood Bank mode provides precise and rapid cell counts for greater confidence in blood product quality. Available as a single module (XN-1000BB) or twin co-primary analyzers (XN-2000BB), the scalable hematology analyzer may be installed as a tabletop analyzer or placed on wagons, and either model may be made even more efficient with the addition of the RU-20 reagent unit.Reported Earnings • May 15Full year 2021 earnings released: EPS JP¥159 (vs JP¥167 in FY 2020)The company reported a mediocre full year result with weaker earnings, although profit margins were flat and revenues improved. Full year 2021 results: Revenue: JP¥305.1b (up 1.0% from FY 2020). Net income: JP¥33.1b (down 5.0% from FY 2020). Profit margin: 11% (in line with FY 2020). Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings.Upcoming Dividend • Mar 23Upcoming Dividend of JP¥36.00 Per ShareWill be paid on the 22nd of June to those who are registered shareholders by the 30th of March. The trailing yield of 0.6% is below the top quartile of German dividend payers (3.3%), and is lower than industry peers (1.0%).お知らせ • Mar 11Sysmex Corporation to Report Fiscal Year 2021 Results on May 12, 2021Sysmex Corporation announced that they will report fiscal year 2021 results on May 12, 2021Is New 90 Day High Low • Feb 25New 90-day low: €86.50The company is down 4.0% from its price of €90.00 on 27 November 2020. The German market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 20% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €43.91 per share.Reported Earnings • Feb 06Third quarter 2021 earnings released: EPS JP¥50.90 (vs JP¥42.64 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: JP¥79.8b (up 6.1% from 3Q 2020). Net income: JP¥10.6b (up 20% from 3Q 2020). Profit margin: 13% (up from 12% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings.Analyst Estimate Surprise Post Earnings • Feb 06Revenue beats expectationsRevenue exceeded analyst estimates by 3.1%. Over the next year, revenue is forecast to grow 8.3%, compared to a 14% growth forecast for the Medical Equipment industry in Germany.お知らせ • Jan 26Roche Holding AG Renews Partnership with Sysmex to Deliver Haematology Testing SolutionsRoche Holding AG announced that, on 14 December, 2020, it signed a Global Business Partnership Agreement (GBP) with Sysmex. Under this new framework, the parties renewed their commitment to the long standing Distribution, Sales and Service (DSS) agreement, allowing Roche to continue to distribute Sysmex haematology products, including instruments and reagents.2 This GBP sees the introduction of an IT Solutions Collaboration Agreement. In the newly defined collaboration, the two companies have agreed to utilise their respective IT platforms to improve customer experience, in the short to mid-term, with a longer term ambition to use the IT systems to lead to improved clinical decision making. The GBP agreement will run until the end of 2030. The burden of blood disorders is very high, not only for patients but for society as a whole. Recent studies estimated that, in Europe, 80 million people suffer from haematological disorders and the economic impact of blood disorders in Europe amounts to EUR 23 billion per year, mostly in healthcare expenditure. Improved management is a key factor to counteract the rise of this economic burden for healthcare and society.Is New 90 Day High Low • Dec 29New 90-day high: €95.50The company is up 18% from its price of €81.00 on 30 September 2020. The German market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €37.40 per share.Is New 90 Day High Low • Dec 05New 90-day high: €93.50The company is up 30% from its price of €72.00 on 04 September 2020. The German market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €37.32 per share.お知らせ • Dec 03Sysmex Corporation to Report Q3, 2021 Results on Feb 03, 2021Sysmex Corporation announced that they will report Q3, 2021 results on Feb 03, 2021Analyst Estimate Surprise Post Earnings • Nov 07Revenue beats expectationsRevenue exceeded analyst estimates by 2.2%. Over the next year, revenue is forecast to grow 8.1%, compared to a 13% growth forecast for the Medical Equipment industry in Germany.Reported Earnings • Nov 07Second quarter 2021 earnings released: EPS JP¥39.09The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: JP¥71.6b (down 3.9% from 2Q 2020). Net income: JP¥8.17b (down 25% from 2Q 2020). Profit margin: 11% (down from 15% in 2Q 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings.Is New 90 Day High Low • Nov 05New 90-day high: €83.50The company is up 34% from its price of €62.50 on 07 August 2020. The German market is down 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €36.77 per share.Is New 90 Day High Low • Oct 12New 90-day high: €83.00The company is up 28% from its price of €65.00 on 14 July 2020. The German market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €36.46 per share.お知らせ • Oct 10Sysmex Corporation to Report Q2, 2021 Results on Nov 05, 2020Sysmex Corporation announced that they will report Q2, 2021 results on Nov 05, 2020お知らせ • Jun 29Sysmex Corporation to Report Q1, 2021 Results on Aug 05, 2020Sysmex Corporation announced that they will report Q1, 2021 results on Aug 05, 2020株主還元0YXDE Medical EquipmentDE 市場7D-4.3%1.0%0.7%1Y-50.0%-26.7%2.2%株主還元を見る業界別リターン: 0YX過去 1 年間で-26.7 % の収益を上げたGerman Medical Equipment業界を下回りました。リターン対市場: 0YXは、過去 1 年間で2.2 % のリターンを上げたGerman市場を下回りました。価格変動Is 0YX's price volatile compared to industry and market?0YX volatility0YX Average Weekly Movement13.1%Medical Equipment Industry Average Movement6.2%Market Average Movement5.9%10% most volatile stocks in DE Market13.2%10% least volatile stocks in DE Market2.8%安定した株価: 0YXの株価は、 German市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 0YXの weekly volatility ( 13% ) は過去 1 年間安定していますが、依然としてGermanの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト196810,533Hisashi Ietsuguwww.sysmex.co.jpシスメックス株式会社は日本で診断機器、試薬、関連ソフトウェアの開発、製造、販売を行っている。同社は、血液学で使用される3分割および5分割の白血球鑑別装置、ラボでの大量検査用の搬送システムを提供している。同社はまた、自動尿粒子分析装置、自動血液凝固分析装置、微量サンプルのアッセイを行う自動免疫化学システム、感染症や腫瘍マーカーの検査試薬、白血病、悪性リンパ腫、HIV/AIDSの診断分析を行うフローサイトメーターも提供している。さらに、リンパ節転移の診断に役立つ情報を検出するがんリンパ節転移検査システム、ラボアッセイサービスも提供している。さらに、診断情報システム用ソフトウェアの開発・販売、施設管理・事務・福祉・遺伝子解析サービスの提供、デジタル医療に関するITソリューション・プラットフォーム・アプリケーションの開発・運用・保守、医療用ロボットに関するマーケティング・開発・設計・製造・販売・アフターサービス、バイオ・医療技術・分子細胞解析に関する医療機器・試薬の販売・アフターサービスなども手掛けている。また、再生医療製品の研究・開発・製造・販売、バイオデバイスの開発・製造・販売、コンピュータソフトウェアの開発・保守・販売、血液DNA検査サービスも行っている。国公立病院、私立病院、大学、研究機関、その他の医療機関などにサービスを提供している。また、約190カ国に製品を輸出している。旧社名は東亜医用電子株式会社で、1998年10月にシスメックス株式会社に社名変更。シスメックス株式会社は1968年に設立され、神戸に本社を置いている。もっと見るSysmex Corporation 基礎のまとめSysmex の収益と売上を時価総額と比較するとどうか。0YX 基礎統計学時価総額€4.67b収益（TTM）€190.36m売上高(TTM)€2.68b24.5xPER（株価収益率1.7xP/Sレシオ0YX は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計0YX 損益計算書（TTM）収益JP¥500.01b売上原価JP¥244.32b売上総利益JP¥255.68bその他の費用JP¥220.23b収益JP¥35.46b直近の収益報告Mar 31, 2026次回決算日Aug 07, 2026一株当たり利益（EPS）57.62グロス・マージン51.14%純利益率7.09%有利子負債／自己資本比率6.3%0YX の長期的なパフォーマンスは？過去の実績と比較を見る配当金2.8%現在の配当利回り63%配当性向0YX 配当は確実ですか？0YX 配当履歴とベンチマークを見る0YX 、いつまでに購入すれば配当金を受け取れますか？Sysmex 配当日配当落ち日Mar 30 2026配当支払日Jun 29 2026配当落ちまでの日数79 days配当支払日までの日数12 days0YX 配当は確実ですか？0YX 配当履歴とベンチマークを見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/16 00:17終値2026/06/16 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Sysmex Corporation 15 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。27 アナリスト機関Masahiro NakanomyoBarclaysKei TakeuchiBofA Global ResearchHidemaru YamaguchiCitigroup Inc24 その他のアナリストを表示
New Risk • Jun 11New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risks Dividend is not well covered by cash flows (108% cash payout ratio). Profit margins are more than 30% lower than last year (7.1% net profit margin).
お知らせ • Jun 06Sysmex Corporation to Report Q1, 2027 Results on Aug 07, 2026Sysmex Corporation announced that they will report Q1, 2027 results on Aug 07, 2026
Valuation Update With 7 Day Price Move • Jun 01Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €8.02, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 17x in the Medical Equipment industry in Germany. Total loss to shareholders of 61% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €7.89 per share.
Reported Earnings • May 20Full year 2026 earnings released: EPS: JP¥56.89 (vs JP¥86.07 in FY 2025)Full year 2026 results: EPS: JP¥56.89 (down from JP¥86.07 in FY 2025). Revenue: JP¥500.0b (down 1.7% from FY 2025). Net income: JP¥35.5b (down 34% from FY 2025). Profit margin: 7.1% (down from 11% in FY 2025). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 5.5% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 30% per year, which means it is performing significantly worse than earnings.
お知らせ • May 15Sysmex Corporation, Annual General Meeting, Jun 26, 2026Sysmex Corporation, Annual General Meeting, Jun 26, 2026.
お知らせ • Apr 02Sysmex Corporation to Report Fiscal Year 2026 Results on May 14, 2026Sysmex Corporation announced that they will report fiscal year 2026 results at 3:30 PM, Tokyo Standard Time on May 14, 2026
New Risk • Jun 11New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risks Dividend is not well covered by cash flows (108% cash payout ratio). Profit margins are more than 30% lower than last year (7.1% net profit margin).
お知らせ • Jun 06Sysmex Corporation to Report Q1, 2027 Results on Aug 07, 2026Sysmex Corporation announced that they will report Q1, 2027 results on Aug 07, 2026
Valuation Update With 7 Day Price Move • Jun 01Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €8.02, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 17x in the Medical Equipment industry in Germany. Total loss to shareholders of 61% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €7.89 per share.
Reported Earnings • May 20Full year 2026 earnings released: EPS: JP¥56.89 (vs JP¥86.07 in FY 2025)Full year 2026 results: EPS: JP¥56.89 (down from JP¥86.07 in FY 2025). Revenue: JP¥500.0b (down 1.7% from FY 2025). Net income: JP¥35.5b (down 34% from FY 2025). Profit margin: 7.1% (down from 11% in FY 2025). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 5.5% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 30% per year, which means it is performing significantly worse than earnings.
お知らせ • May 15Sysmex Corporation, Annual General Meeting, Jun 26, 2026Sysmex Corporation, Annual General Meeting, Jun 26, 2026.
お知らせ • Apr 02Sysmex Corporation to Report Fiscal Year 2026 Results on May 14, 2026Sysmex Corporation announced that they will report fiscal year 2026 results at 3:30 PM, Tokyo Standard Time on May 14, 2026
お知らせ • Mar 26Denka Company Limited (TSE:4061) completed the acquisition of 77.65% stake in KAINOS Laboratories, Inc. (TSE:4556) from a group of shareholders.Denka Company Limited (TSE:4061) proposed to acquire 77.65% stake in KAINOS Laboratories, Inc. (TSE:4556) from a group of shareholders for ¥7.9 billion on February 6, 2026. A cash consideration of ¥7.89 billion valued at ¥2285 per share will be paid by Denka Company Limited. As part of consideration, ¥7.89 billion is paid towards common equity of KAINOS Laboratories, Inc. Denka Company Limited intends to launch a Squeeze-Out Procedures, if it acquires the minimum tender shares (1,990,000 shares) and fails to acquire all of the KAINOS Laboratories, Inc's Shares (excluding the Shares Agreed Not to Be Tendered and treasury shares). The transaction is subject to minimum tender. The expected completion of the transaction is March 25, 2026. Sumitomo Mitsui Banking Corporation acted as financial advisor for Denka Company Limited. AGS Consulting Co., Ltd. acted as financial advisor for KAINOS Laboratories, Inc. Nagashima Ohno & Tsunematsu acted as legal advisor for KAINOS Laboratories, Inc. TMI Associates acted as legal advisor for KAINOS Laboratories, Inc. Mizuho Securities Co., Ltd. acted as financial advisor for KAINOS Laboratories, Inc. Denka Company Limited (TSE:4061) completed the acquisition of 77.65% stake in KAINOS Laboratories, Inc. (TSE:4556) from a group of shareholders on March 25, 2026. Upon closing of the offer period, 3,223,919 shares were tendered. Since it is more than the minimum number of shares to be purchased (1,990,000 shares), Denka Company Limited will purchase all of the Tendered Share Certificates and intends to implement a series of procedures for the purpose of making the Tender Offeror the sole shareholder of KAINOS Laboratories, Inc. As of today, the KAINOS Laboratories, Inc's Shares are listed on the Standard Market of the Tokyo Stock Exchange. If the procedures are implemented, the KAINOS Laboratories, Inc's Shares will be delisted pursuant to the prescribed procedures, in accordance with the criteria for delisting of Tokyo Stock Exchange. KAINOS Laboratories, Inc's Shares, after being delisted, will no longer be traded on the Standard Market of the Tokyo Stock Exchange.
お知らせ • Mar 05Sysmex Corporation (TSE:6869) announces an Equity Buyback for 30,000,000 shares, representing 4.81% for ¥30,000 million.Sysmex Corporation (TSE:6869) announces a share repurchase program. Under the program, the company will repurchase up to 30,000,000 shares, representing 4.81% of its issued share capital, for ¥30,000 million. The program will be valid till September 18, 2026. The purpose of the program is to improve capital efficiency and enhance shareholder returns as well as active business investment for our future growth. The purchased shares will be cancelled. As of December 31, 2025, the company had 623,180,031 outstanding shares (excluding treasury stock) and 6,300,045 treasury shares.
お知らせ • Feb 13Sysmex Corporation Revises Consolidated Earnings Guidance for the Year Ending March 31, 2026Sysmex Corporation revised consolidated earnings guidance for the year ending March 31, 2026. For the year period, the company expects net sales of JPY 500,000 million compared to previous guidance of JPY 510,000 million, operating profit of JPY 62,000 million compared to previous guidance of JPY 76,000 million and profit attributable to owners of the parent of JPY 41,000 million or JPY 65.77 per basic share compared to previous guidance of JPY 45,000 million or JPY 72.19 per basic share.
お知らせ • Feb 12Sysmex Corporation Announces Executive and Board Changes, Effective April 1, 2026Sysmex Corporation announced that it has resolved, at a meeting of the Board of Directors held on February 12, 2026, to change the representative directors as stated below. Reasons for Change. To further strengthen management structure in order to enhance corporate value. Iwane Matsui has been newly appointed as the President (Representative Director), while previously serving as Member of the Managing Board and Senior Executive Officer, Senior Managing Director. Kaoru Asano appointed as the Member of the Managing Board, from currently holding the title of President (Representative Director). Effective Date of Transfer: April 1, 2026. Kaoru Asano is scheduled to resign from the Member of the Managing Board at the Ordinary General Meeting of Shareholders to be held in June 2026 and subsequently serve as Senior Executive Advisor. There are no changes to Hisashi Ietsugu's current position as Chairperson and Group CEO. Iwane Matsui was born on January 1, 1961, and graduated from Kobe University with a Bachelor of Faculty of Law in March 1985. He joined TOA Medical Electronics Co. Ltd. (presently Sysmex Corporation) in April 1985. His career progressed through various roles, including serving as President of Sysmex Europe GmbH (presently Sysmex Europe SE) from 2001 to 2005, and later as Executive Vice Chairman & CEO of Sysmex Europe GmbH from 2005 to 2007. He held the position of Executive Vice President of the Customer Support Division from 2007 to 2009, followed by Executive Vice President of the IVD Business Strategy Division from 2009 to 2011. From 2011 to 2013, he served as Executive Officer and Executive Vice President of Corporate Business Planning, and from 2013 to 2015, he was an Executive Officer and Executive Vice President of International Business Management. He then became a Senior Executive Officer from 2017 to 2019, and a Managing Director in 2019. He was appointed as a Member of the Managing Board and Senior Executive Officer in June 2019 and has held the same position since April 2023, also serving as a Senior Managing Director.
お知らせ • Feb 09Denka Company Limited (TSE:4061) proposed to acquire 77.65% stake in KAINOS Laboratories, Inc. (TSE:4556) from a group of shareholders for ¥7.9 billion.Denka Company Limited (TSE:4061) proposed to acquire 77.65% stake in KAINOS Laboratories, Inc. (TSE:4556) from a group of shareholders for ¥7.9 billion on February 6, 2026. A cash consideration of ¥7.89 billion valued at ¥2285 per share will be paid by Denka Company Limited. As part of consideration, ¥7.89 billion is paid towards common equity of KAINOS Laboratories, Inc. The transaction is subject to minimum tender. The expected completion of the transaction is March 25, 2026. Sumitomo Mitsui Banking Corporation acted as financial advisor for Denka Company Limited. AGS Consulting Co., Ltd. acted as financial advisor for KAINOS Laboratories, Inc. Nagashima Ohno & Tsunematsu acted as legal advisor for KAINOS Laboratories, Inc. TMI Associates acted as legal advisor for KAINOS Laboratories, Inc. Mizuho Securities Co., Ltd. acted as financial advisor for KAINOS Laboratories, Inc.
お知らせ • Dec 05Sysmex Corporation to Report Q3, 2026 Results on Feb 12, 2026Sysmex Corporation announced that they will report Q3, 2026 results on Feb 12, 2026
お知らせ • Nov 06+ 2 more updatesSysmex Corporation Revises Consolidated Earnings Guidance for the Year Ending March 31, 2026Sysmex Corporation revised consolidated earnings guidance for the year ending March 31, 2026. For the year ending March 31, 2026, the company expects net sales of JPY 510,000 million compared to previous guidance of JPY 535,000 million, operating profit of JPY 76,000 million compared to previous guidance of JPY 91,500 million and profit attributable to owners of the parent of JPY 45,000 million or JPY 72.19 per basic share compared to previous guidance of JPY 57,000 million or JPY 91.40 per basic share. Reasons for Forecast Revision: Although the company worked to control selling, general and administrative (SG&A) expenses, the company was unable to offset the decline in profit resulting from lower-than-expected net sales. As a result, operating profit, profit before tax, and profit attributable to owners of the parent all fell below the previous forecast. As for its forecast for the full fiscal year ending March 31, 2026, it will continue working to improve profitability and control SG&A expenses. However, given the expectation that sales in the China and Japan regions will remain below initial projections, the company is revising its forecast to reflect anticipated declines in net sales, operating profit, profit before tax, and profit attributable to owners of the parent.
お知らせ • Sep 04Sysmex Corporation to Report Q2, 2026 Results on Nov 05, 2025Sysmex Corporation announced that they will report Q2, 2026 results on Nov 05, 2025
お知らせ • Jun 25+ 1 more updateSysmex America, Inc. Receives FDA Clearance for Automated Blood Coagulation Analyzer CN-6000™?Sysmex America Inc. has received FDA clearance for the CN-6000 Automated Blood Coagulation Analyzer. This clearance includes the reagent products used in five commonly performed hemostasis tests: Prothrombin Time (PT) and PT INR with Dade®? Innovin®? Activated Partial Thromboplastin Time (APTT) with Dade®? Actin®? FSL; Fibrinogen (Fbg) with Dade®? Thrombin Reagent; Antithrombin (AT) with INNOVANCE®? Antithrombin; D-dimer with INNOVANCE D-Dimmer. Laboratories with high workloads may opt for the optional sampler that provides an expandable sample loading capacity. Sysmex will continue efforts to obtain market authorization for the Automated Blood Coagulation Analyzer CN-3000 and additional reagent applications.
お知らせ • Jun 07Sysmex Corporation to Report Q1, 2026 Results on Aug 06, 2025Sysmex Corporation announced that they will report Q1, 2026 results on Aug 06, 2025
お知らせ • May 15Sysmex Corporation, Annual General Meeting, Jun 27, 2025Sysmex Corporation, Annual General Meeting, Jun 27, 2025.
お知らせ • Feb 28Sysmex Corporation to Report Fiscal Year 2025 Results on May 14, 2025Sysmex Corporation announced that they will report fiscal year 2025 results on May 14, 2025
Reported Earnings • Nov 09Second quarter 2025 earnings released: EPS: JP¥24.01 (vs JP¥21.60 in 2Q 2024)Second quarter 2025 results: EPS: JP¥24.01 (up from JP¥21.60 in 2Q 2024). Revenue: JP¥130.5b (up 11% from 2Q 2024). Net income: JP¥15.0b (up 10% from 2Q 2024). Profit margin: 12% (in line with 2Q 2024). Revenue is forecast to grow 8.0% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.
お知らせ • Oct 03D-Group S.p.A. acquired an unknown minority stake in Dasit S.p.A. from Sysmex Corporation (TSE:6869).D-Group S.p.A. acquired an unknown minority stake in Dasit S.p.A. from Sysmex Corporation (TSE:6869) on October 2, 2024. Francesco Stella of Hogan Lovells acted as legal advisor for Sysmex Corporation. D-Group S.p.A. completed the acquisition of an unknown minority stake in Dasit S.p.A. from Sysmex Corporation (TSE:6869) on October 2, 2024.
New Risk • Oct 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Upcoming Dividend • Sep 20Upcoming dividend of JP¥15.00 per shareEligible shareholders must have bought the stock before 27 September 2024. Payment date: 04 December 2024. Payout ratio is a comfortable 34% and the cash payout ratio is 87%. Trailing yield: 1.1%. Lower than top quartile of German dividend payers (4.8%). Lower than average of industry peers (1.9%).
Reported Earnings • Aug 08First quarter 2025 earnings released: EPS: JP¥17.69 (vs JP¥13.73 in 1Q 2024)First quarter 2025 results: EPS: JP¥17.69 (up from JP¥13.73 in 1Q 2024). Revenue: JP¥111.9b (up 17% from 1Q 2024). Net income: JP¥11.0b (up 28% from 1Q 2024). Profit margin: 9.9% (in line with 1Q 2024). Revenue is forecast to grow 7.8% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.
Buy Or Sell Opportunity • Aug 04Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 14% to €14.50. The fair value is estimated to be €18.15, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 7.8%. For the next 3 years, revenue is forecast to grow by 8.0% per annum. Earnings are also forecast to grow by 13% per annum over the same time period.
Declared Dividend • Jul 11Final dividend of JP¥15.00 announcedShareholders will receive a dividend of JP¥15.00. Ex-date: 27th September 2024 Payment date: 4th December 2024 Dividend yield will be 108%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by earnings (35% earnings payout ratio) but not covered by cash flows (136% cash payout ratio). The dividend has increased by an average of 16% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 44% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
お知らせ • Jun 27+ 2 more updatesSysmex Corporation to Report Q3, 2025 Results on Feb 12, 2025Sysmex Corporation announced that they will report Q3, 2025 results on Feb 12, 2025
Reported Earnings • Jun 26Full year 2024 earnings released: EPS: JP¥238 (vs JP¥72.94 in FY 2023)Full year 2024 results: EPS: JP¥238 (up from JP¥72.94 in FY 2023). Revenue: JP¥461.5b (up 12% from FY 2023). Net income: JP¥49.6b (up 8.4% from FY 2023). Profit margin: 11% (in line with FY 2023). Revenue is forecast to grow 8.0% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.
お知らせ • May 12Sysmex Corporation, Annual General Meeting, Jun 21, 2024Sysmex Corporation, Annual General Meeting, Jun 21, 2024.
Reported Earnings • May 10Full year 2024 earnings released: EPS: JP¥238 (vs JP¥72.94 in FY 2023)Full year 2024 results: EPS: JP¥238 (up from JP¥72.94 in FY 2023). Revenue: JP¥461.5b (up 12% from FY 2023). Net income: JP¥49.6b (up 8.4% from FY 2023). Profit margin: 11% (in line with FY 2023). Revenue is forecast to grow 7.3% p.a. on average during the next 3 years, compared to a 7.0% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.
Buy Or Sell Opportunity • Apr 26Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 9.4% to €14.50. The fair value is estimated to be €18.41, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 9.5%. For the next 3 years, revenue is forecast to grow by 7.9% per annum. Earnings are also forecast to grow by 13% per annum over the same time period.
Buy Or Sell Opportunity • Apr 11Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 15% to €14.80. The fair value is estimated to be €18.64, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 9.5%. For the next 3 years, revenue is forecast to grow by 7.9% per annum. Earnings are also forecast to grow by 13% per annum over the same time period.
New Risk • Mar 27New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. Cash payout ratio: 293% Dividend yield: 3.1% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company.
Upcoming Dividend • Mar 21Upcoming dividend of JP¥42.00 per shareEligible shareholders must have bought the stock before 28 March 2024. Payment date: 26 June 2024. Payout ratio is a comfortable 38% and the cash payout ratio is 98%. Trailing yield: 1.0%. Lower than top quartile of German dividend payers (5.0%). Lower than average of industry peers (1.6%).
お知らせ • Mar 08Sysmex Corporation to Report Fiscal Year 2024 Results on May 09, 2024Sysmex Corporation announced that they will report fiscal year 2024 results on May 09, 2024
Reported Earnings • Feb 11Third quarter 2024 earnings released: EPS: JP¥58.90 (vs JP¥53.51 in 3Q 2023)Third quarter 2024 results: EPS: JP¥58.90 (up from JP¥53.51 in 3Q 2023). Revenue: JP¥113.8b (up 8.7% from 3Q 2023). Net income: JP¥12.3b (up 9.7% from 3Q 2023). Profit margin: 11% (in line with 3Q 2023). Revenue is forecast to grow 7.7% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.
お知らせ • Feb 09Sysmex Corporation Reaffirm Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2024Sysmex Corporation announced year-end dividend for the fiscal year ending March 31, 2024, with a record date of March 31, 2024, will be paid on the shares before the stock split, because the effective date of the share split is April 1, 2024. The year-end dividend forecast for the fiscal year ending March 31, 2024 remains unchanged from that the announcement on May 11, 2023, which forecasts the year-end dividend of ¥42 per share.
お知らせ • Nov 30Sysmex Corporation to Report Q3, 2024 Results on Feb 09, 2024Sysmex Corporation announced that they will report Q3, 2024 results on Feb 09, 2024
Reported Earnings • Nov 09Second quarter 2024 earnings released: EPS: JP¥64.81 (vs JP¥76.28 in 2Q 2023)Second quarter 2024 results: EPS: JP¥64.81 (down from JP¥76.28 in 2Q 2023). Revenue: JP¥117.3b (up 8.7% from 2Q 2023). Net income: JP¥13.6b (down 15% from 2Q 2023). Profit margin: 12% (down from 15% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 7.6% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.
Upcoming Dividend • Sep 22Upcoming dividend of JP¥42.00 per share at 1.1% yieldEligible shareholders must have bought the stock before 28 September 2023. Payment date: 05 December 2023. Payout ratio is a comfortable 36% and this is well supported by cash flows. Trailing yield: 1.1%. Lower than top quartile of German dividend payers (4.8%). Lower than average of industry peers (2.0%).
お知らせ • Sep 08Sysmex Corporation to Report Q2, 2024 Results on Nov 08, 2023Sysmex Corporation announced that they will report Q2, 2024 results on Nov 08, 2023
Reported Earnings • Aug 09First quarter 2024 earnings released: EPS: JP¥41.20 (vs JP¥38.38 in 1Q 2023)First quarter 2024 results: EPS: JP¥41.20 (up from JP¥38.38 in 1Q 2023). Revenue: JP¥95.4b (up 11% from 1Q 2023). Net income: JP¥8.62b (up 7.4% from 1Q 2023). Profit margin: 9.0% (down from 9.3% in 1Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 7.3% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.
お知らせ • Jun 03Sysmex Corporation to Report Q1, 2024 Results on Aug 08, 2023Sysmex Corporation announced that they will report Q1, 2024 results at 3:00 PM, Tokyo Standard Time on Aug 08, 2023
Reported Earnings • May 15Full year 2023 earnings released: EPS: JP¥219 (vs JP¥211 in FY 2022)Full year 2023 results: EPS: JP¥219 (up from JP¥211 in FY 2022). Revenue: JP¥410.5b (up 13% from FY 2022). Net income: JP¥45.8b (up 3.8% from FY 2022). Profit margin: 11% (in line with FY 2022). Revenue is forecast to grow 7.8% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.
お知らせ • May 13Sysmex Corporation, Annual General Meeting, Jun 23, 2023Sysmex Corporation, Annual General Meeting, Jun 23, 2023.
Upcoming Dividend • Mar 23Upcoming dividend of JP¥40.00 per share at 0.9% yieldEligible shareholders must have bought the stock before 30 March 2023. Payment date: 27 June 2023. Payout ratio is a comfortable 36% but the company is paying out more than the cash it is generating. Trailing yield: 0.9%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (1.7%).
Reported Earnings • Feb 13Third quarter 2023 earnings released: EPS: JP¥53.51 (vs JP¥50.96 in 3Q 2022)Third quarter 2023 results: EPS: JP¥53.51 (up from JP¥50.96 in 3Q 2022). Revenue: JP¥104.7b (up 16% from 3Q 2022). Net income: JP¥11.2b (up 5.1% from 3Q 2022). Profit margin: 11% (down from 12% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 7.4% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
お知らせ • Feb 07Sysmex Corporation Announces Management ChangesSysmex Corporation announced that it has resolved, at a meeting of the Board of Directors held on February 7, 2023, to change the representative directors. Kaoru Asano appointed as President (Representative Director) from Member of the Managing Board and Senior Executive Officer, Senior Managing Director, CTO. Appointment Date (Scheduled): April 1, 2023. Date of birth: October 19, 1958. Education: Graduate School of Engineering Osaka University, Division of Electronic Engineering. 2021- Member of the Managing Board and Senior Executive Officer, Senior Managing Director, CTO; 2018-2021 Member of the Managing Board and Senior Executive Officer, Senior Managing Director, COO LS Business Unit and CTO; 2017-2018 Member of the Managing Board and Senior Executive Officer, Senior Managing Director; 2015-2017 Member of the Managing Board and Senior Executive Officer, Managing Director; 2014-2015 Appointed Member of the Managing Board and Senior Executive Officer. 2013-2014 -Appointed Senior Executive Officer, Executive Vice President of Central Research Laboratories; 2011-2013 Appointed Executive Officer, Executive Vice President of R&D Strategic Planning; 2009-2011 Appointed Executive Officer, Executive Vice President of Central Research Laboratories; Aug. 1987 Joined TOA Medical Electronics (presently Sysmex Corporation); Apr. 1983 Joined Kawasaki Heavy Industries Ltd.; March 1983 Graduated from Osaka University. Hisashi Ietsugu: Current: Chairman and CEO (Representative Director); New: Chairman and Group CEO, (Representative Director).
お知らせ • Jan 11Sysmex America, Inc. Appoints Chris Cappella as Chief Financial OfficerSysmex America Inc. announced that Chris Cappella has joined the Company as Chief Financial Officer. He will lead Sysmex America's regional finance organization and financial activities including accounting and controllership, financial planning and analysis, tax, internal audit and treasury. to joining Sysmex, Chris held a variety of finance leadership roles at Roche, most recently as the vice president of finance for Core Lab. At Roche, he was instrumental in driving growth through the cross-functional integration of agile strategies. Before his time at Roche, Chris was a finance manager at Brightpoint Inc. He started his career at Ernst & Young and is a Certified Public Accountant.
お知らせ • Dec 01Sysmex Corporation to Report Q3, 2023 Results on Feb 09, 2023Sysmex Corporation announced that they will report Q3, 2023 results on Feb 09, 2023
Reported Earnings • Nov 17Second quarter 2023 earnings released: EPS: JP¥76.28 (vs JP¥58.61 in 2Q 2022)Second quarter 2023 results: EPS: JP¥76.28 (up from JP¥58.61 in 2Q 2022). Revenue: JP¥108.0b (up 21% from 2Q 2022). Net income: JP¥16.0b (up 30% from 2Q 2022). Profit margin: 15% (up from 14% in 2Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 7.7% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
Board Change • Nov 17Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 5 independent directors. 7 non-independent directors. Independent Outside Member of the Managing Board Hidekazu Fukumoto was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
Reported Earnings • Nov 11Second quarter 2023 earnings released: EPS: JP¥76.28 (vs JP¥58.61 in 2Q 2022)Second quarter 2023 results: EPS: JP¥76.28 (up from JP¥58.61 in 2Q 2022). Revenue: JP¥108.0b (up 21% from 2Q 2022). Net income: JP¥16.0b (up 30% from 2Q 2022). Profit margin: 15% (up from 14% in 2Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 7.7% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
Upcoming Dividend • Sep 22Upcoming dividend of JP¥40.00 per shareEligible shareholders must have bought the stock before 29 September 2022. Payment date: 06 December 2022. Payout ratio is a comfortable 38% but the company is paying out more than the cash it is generating. Trailing yield: 1.0%. Lower than top quartile of German dividend payers (5.1%). Lower than average of industry peers (1.8%).
お知らせ • Sep 14Sysmex Corporation to Report Q2, 2023 Results on Nov 09, 2022Sysmex Corporation announced that they will report Q2, 2023 results on Nov 09, 2022
Reported Earnings • Aug 05First quarter 2023 earnings released: EPS: JP¥38.38 (vs JP¥47.81 in 1Q 2022)First quarter 2023 results: EPS: JP¥38.38 (down from JP¥47.81 in 1Q 2022). Revenue: JP¥86.0b (up 8.4% from 1Q 2022). Net income: JP¥8.03b (down 20% from 1Q 2022). Profit margin: 9.3% (down from 13% in 1Q 2022). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 14%, compared to a 7.2% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 6% per year whereas the company’s share price has increased by 5% per year.
お知らせ • Jun 18Sysmex Corporation to Report Q1, 2023 Results on Aug 04, 2022Sysmex Corporation announced that they will report Q1, 2023 results on Aug 04, 2022
Buying Opportunity • Jun 17Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 14%. The fair value is estimated to be €69.73, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.6% over the last 3 years. Earnings per share has grown by 2.7%. For the next 3 years, revenue is forecast to grow by 8.1% per annum. Earnings is also forecast to grow by 12% per annum over the same time period.
Reported Earnings • May 15Full year 2022 earnings released: EPS: JP¥211 (vs JP¥159 in FY 2021)Full year 2022 results: EPS: JP¥211 (up from JP¥159 in FY 2021). Revenue: JP¥363.8b (up 19% from FY 2021). Net income: JP¥44.1b (up 33% from FY 2021). Profit margin: 12% (up from 11% in FY 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 8.7%, compared to a 7.1% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 1% per year.
お知らせ • May 14Sysmex Corporation, Annual General Meeting, Jun 24, 2022Sysmex Corporation, Annual General Meeting, Jun 24, 2022.
Board Change • Apr 27Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, 4 were independent directors. The company's board is composed of: 5 independent directors. 7 non-independent directors. Independent Outside Member of the Managing Board Hidekazu Fukumoto was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
お知らせ • Apr 04Sysmex Corporation to Report Fiscal Year 2022 Results on May 12, 2022Sysmex Corporation announced that they will report fiscal year 2022 results at 3:00 PM, Tokyo Standard Time on May 12, 2022
Upcoming Dividend • Mar 23Upcoming dividend of JP¥37.00 per shareEligible shareholders must have bought the stock before 30 March 2022. Payment date: 28 June 2022. Payout ratio is a comfortable 36% and this is well supported by cash flows. Trailing yield: 0.9%. Lower than top quartile of German dividend payers (3.6%). Lower than average of industry peers (1.1%).
Buying Opportunity • Mar 12Now 23% undervalued after recent price dropOver the last 90 days, the stock is down 43%. The fair value is estimated to be JP¥81.89, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.2% per annum over the last 3 years. Earnings per share has been flat over the last 3 years.
Valuation Update With 7 Day Price Move • Mar 02Investor sentiment improved over the past weekAfter last week's 17% share price gain to €74.00, the stock trades at a forward P/E ratio of 38x. Average forward P/E is 34x in the Medical Equipment industry in Germany. Total returns to shareholders of 43% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €86.16 per share.
Reported Earnings • Feb 11Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: EPS: JP¥50.96 (up from JP¥50.90 in 3Q 2021). Revenue: JP¥90.1b (up 13% from 3Q 2021). Net income: JP¥10.7b (flat on 3Q 2021). Profit margin: 12% (down from 13% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 8.9%, compared to a 12% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has increased by 14% per year, which means it is well ahead of earnings.
Valuation Update With 7 Day Price Move • Jan 08Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to €95.50, the stock trades at a forward P/E ratio of 54x. Average forward P/E is 36x in the Medical Equipment industry in Germany. Total returns to shareholders of 127% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €75.84 per share.
Reported Earnings • Nov 11Second quarter 2022 earnings released: EPS JP¥58.61 (vs JP¥39.09 in 2Q 2021)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2022 results: Revenue: JP¥89.4b (up 25% from 2Q 2021). Net income: JP¥12.3b (up 50% from 2Q 2021). Profit margin: 14% (up from 11% in 2Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 28% per year, which means it is well ahead of earnings.
Upcoming Dividend • Sep 22Upcoming dividend of JP¥37.00 per shareEligible shareholders must have bought the stock before 29 September 2021. Payment date: 01 December 2021. Trailing yield: 0.5%. Lower than top quartile of German dividend payers (3.2%). Lower than average of industry peers (0.8%).
Valuation Update With 7 Day Price Move • Sep 14Investor sentiment improved over the past weekAfter last week's 18% share price gain to €109, the stock trades at a forward P/E ratio of 58x. Average forward P/E is 47x in the Medical Equipment industry in Germany. Total returns to shareholders of 51% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €94.76 per share.
お知らせ • Jun 03Sysmex America Adds FDA-Cleared XN-10 Blood Bank Mode to Hematology Solutions PortfolioSysmex America Inc., has added the FDA-cleared XN-10 Automated Hematology Analyzer with Blood Bank mode to its portfolio of hematology solutions. This latest analyzer supports red blood cell and platelet component testing and provides an automated complete blood count with differential for whole blood samples. The company is the first and only original equipment manufacturer of Automated Hematology devices to receive FDA-cleared intended use claims for the Blood Center/Blood Bank market. The XN Blood Bank mode is intended for use in blood processing centers for QC release testing of post-processed components. Blood component quality is key in transfusion medicine and blood product manufacturing. Sysmex America's XN Blood Bank mode is a holistic solution that offers accurate cell counts on products that are key to blood centers and blood banks. With no sample preparation or pre-dilution required, the XN Blood Bank mode provides precise and rapid cell counts for greater confidence in blood product quality. Available as a single module (XN-1000BB) or twin co-primary analyzers (XN-2000BB), the scalable hematology analyzer may be installed as a tabletop analyzer or placed on wagons, and either model may be made even more efficient with the addition of the RU-20 reagent unit.
Reported Earnings • May 15Full year 2021 earnings released: EPS JP¥159 (vs JP¥167 in FY 2020)The company reported a mediocre full year result with weaker earnings, although profit margins were flat and revenues improved. Full year 2021 results: Revenue: JP¥305.1b (up 1.0% from FY 2020). Net income: JP¥33.1b (down 5.0% from FY 2020). Profit margin: 11% (in line with FY 2020). Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings.
Upcoming Dividend • Mar 23Upcoming Dividend of JP¥36.00 Per ShareWill be paid on the 22nd of June to those who are registered shareholders by the 30th of March. The trailing yield of 0.6% is below the top quartile of German dividend payers (3.3%), and is lower than industry peers (1.0%).
お知らせ • Mar 11Sysmex Corporation to Report Fiscal Year 2021 Results on May 12, 2021Sysmex Corporation announced that they will report fiscal year 2021 results on May 12, 2021
Is New 90 Day High Low • Feb 25New 90-day low: €86.50The company is down 4.0% from its price of €90.00 on 27 November 2020. The German market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 20% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €43.91 per share.
Reported Earnings • Feb 06Third quarter 2021 earnings released: EPS JP¥50.90 (vs JP¥42.64 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: JP¥79.8b (up 6.1% from 3Q 2020). Net income: JP¥10.6b (up 20% from 3Q 2020). Profit margin: 13% (up from 12% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings.
Analyst Estimate Surprise Post Earnings • Feb 06Revenue beats expectationsRevenue exceeded analyst estimates by 3.1%. Over the next year, revenue is forecast to grow 8.3%, compared to a 14% growth forecast for the Medical Equipment industry in Germany.
お知らせ • Jan 26Roche Holding AG Renews Partnership with Sysmex to Deliver Haematology Testing SolutionsRoche Holding AG announced that, on 14 December, 2020, it signed a Global Business Partnership Agreement (GBP) with Sysmex. Under this new framework, the parties renewed their commitment to the long standing Distribution, Sales and Service (DSS) agreement, allowing Roche to continue to distribute Sysmex haematology products, including instruments and reagents.2 This GBP sees the introduction of an IT Solutions Collaboration Agreement. In the newly defined collaboration, the two companies have agreed to utilise their respective IT platforms to improve customer experience, in the short to mid-term, with a longer term ambition to use the IT systems to lead to improved clinical decision making. The GBP agreement will run until the end of 2030. The burden of blood disorders is very high, not only for patients but for society as a whole. Recent studies estimated that, in Europe, 80 million people suffer from haematological disorders and the economic impact of blood disorders in Europe amounts to EUR 23 billion per year, mostly in healthcare expenditure. Improved management is a key factor to counteract the rise of this economic burden for healthcare and society.
Is New 90 Day High Low • Dec 29New 90-day high: €95.50The company is up 18% from its price of €81.00 on 30 September 2020. The German market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €37.40 per share.
Is New 90 Day High Low • Dec 05New 90-day high: €93.50The company is up 30% from its price of €72.00 on 04 September 2020. The German market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €37.32 per share.
お知らせ • Dec 03Sysmex Corporation to Report Q3, 2021 Results on Feb 03, 2021Sysmex Corporation announced that they will report Q3, 2021 results on Feb 03, 2021
Analyst Estimate Surprise Post Earnings • Nov 07Revenue beats expectationsRevenue exceeded analyst estimates by 2.2%. Over the next year, revenue is forecast to grow 8.1%, compared to a 13% growth forecast for the Medical Equipment industry in Germany.
Reported Earnings • Nov 07Second quarter 2021 earnings released: EPS JP¥39.09The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: JP¥71.6b (down 3.9% from 2Q 2020). Net income: JP¥8.17b (down 25% from 2Q 2020). Profit margin: 11% (down from 15% in 2Q 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings.
Is New 90 Day High Low • Nov 05New 90-day high: €83.50The company is up 34% from its price of €62.50 on 07 August 2020. The German market is down 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €36.77 per share.
Is New 90 Day High Low • Oct 12New 90-day high: €83.00The company is up 28% from its price of €65.00 on 14 July 2020. The German market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €36.46 per share.
お知らせ • Oct 10Sysmex Corporation to Report Q2, 2021 Results on Nov 05, 2020Sysmex Corporation announced that they will report Q2, 2021 results on Nov 05, 2020
お知らせ • Jun 29Sysmex Corporation to Report Q1, 2021 Results on Aug 05, 2020Sysmex Corporation announced that they will report Q1, 2021 results on Aug 05, 2020
